top of page
Browse by category
Search
Survey finds 93.4% of bariatric patients vs 51.4% of GLP-1 patients have the same treatment again
Over 93% of bariatric patients said they would undergo bariatric surgery again, compared with just over half of those who said they would...
More than half of US adults could benefit from GLP-1 medications
More than half of US adults, an estimated that 137 million people, are eligible for semagludtide for weight loss, diabetes management, or...
GLP-1 RAs found to shrink heart muscle in mice and human cells
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may be associated with shrinking the human heart and other muscles, according to a...
GLP-1 RAs show cardiovascular benefits beyond weight loss
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) continue to show cardiovascular benefits beyond weight loss, according to several...
GLP-1 RAs may be effective in helping people drink less alcohol
A study led by researchers at the University of Nottingham has found that glucagon-like peptide-1 receptor agonists use (GLP-1 RAs) may...
GLP-1s associated with higher risk of major depression, increased risk for anxiety and an elevated risk for suicidal behaviour
Patients on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) - Victoza (Liraglutide 1.8mg), Saxenda (Liraglutide 3mg), Ozempic...
Omada survey finds only 18% of respondents who discontinued GLP-1s achieved their weight loss goals
Omada Health has released findings from an attitudinal survey of 1,000 non-Omada members to better understand the needs of consumers...
Browse by tag
bottom of page